Trial Profile
Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary) ; Carboplatin; Doxorubicin liposomal
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms INOVATYON
- 09 Feb 2023 Results hypothesing that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). published in the British Journal of Cancer
- 08 Feb 2022 Status changed from active, no longer recruiting to completed.
- 21 May 2021 This trial has been completed in Finland, according to European Clinical Trials Database.